Depression is a leading cause of disability worldwide and is a major contributor to the overall global burden of disease. Depression is a common mental disorder. Globally, more than 264 million people of all ages suffer from depression.

Mental health issues affect billions of people across every corner of the globe, touching every community and every family, and mounting evidence shows the issue is worsening.

We estimate that if medical solutions can be made available faster and more widely relative to our current baseline, it could lead to cumulative increase in global income of almost 9 trillion dollars by end-2025, benefitting all economies and reducing divergence.

Although many new refinements to TRD treatments have been developed in the past decades, their efficacy has not improved over time. Moreover, predicting who is most likely to benefit from which interventions or approaches is not currently possible. People are often exposed to different forms of TRD help before they find one that works for them.

Numerous studies have provided insights into the neuroprotective effects of medicinal mushrooms, which are attributed to their antioxidant, anti-neuroinflammatory, cholinesterase inhibitory and neuroprotective properties.

The global anxiety disorders and depression treatment market size was valued at USD 15.2 billion in 2015 and is anticipated to show steady growth due to the increasing prevalence of anxiety disorder and depression worldwide. Rising demand for antidepressants due to minimum side effects associated with these medications and growing awareness levels amongst the consumers are contributing toward the growth.

• Dominant players such as Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and others involved in developing targeted TRD therapeutics.

• The Treatment-Resistant Depression market is expected to show positive growth, mainly attributed to an increased number of TRD cases and the expected launch of therapies such as AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.

• With a novel mechanism of action, these therapies may change the Treatment-Resistant Depression treatment regimen by 2030.